Tango Therapeutics Releases Early Clinical Trial Results
Tango Therapeutics has announced the initial safety and efficacy findings from its Phase 1/2 combination trial. This study is evaluating vopimetostat alongside RAS(ON) inhibitors from Revolution Medicines. The details of these preliminary results were made public through an SEC filing.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.